At the IGTP TODAY

News

- Research

Type 1 diabetes research sheds light on biomarkers in partial remission phase

Researchers from the IGTP have led a comprehensive review study on biomarkers for the often-overlooked partial remission phase of type 1 diabetes, in collaboration with experts in β-cell biology and regeneration from the Diabetes Research Institute in Miami. The study has been published in the journal Trends in Endocrinology and Metabolism.

Artificial intelligence and advanced therapies are the focus of the ICS Conference, hosted by IGTP

The 14th Research Conference of the ICS focused on the transformative potential of research in the health system and awarded prizes to eight researchers. Antoni Bayés and Alejandro Bustamante, who work at the Hospital and researchers at IGTP, were awarded a prize for the best hospital scientific career and ICS young researcher, respectively.

GCAT takes part in one of the projects funded by Fundació La Marató de 3Cat

The funds raised in the 2022 edition of La Marató de 3Cat will enable 71 research teams to conduct 37 projects in cardiovascular health to advance in the prevention, diagnosis, and treatment of diseases that represent the leading cause of death in developed countries. One of the awarded projects involves the participation of researchers from the GCAT of the IGTP, and is coordinated by Dr Camille Lassale from ISGlobal.

- Innovation

Nimble Diagnostics secures a €2.5 million grant from the EIC Accelerator programme

Nimble Diagnostics has been awarded a €2.5 million grant from EIC Accelerator, a funding programme of the European Innovation Council and SMEs Executive Agency (EISMEA). This spin-off from the Germans Trias i Pujol Research Institute (IGTP), the Polytechnic University of Catalonia - BarcelonaTech (UPC) and the University of Barcelona (UB), is among the 47 selected companies from 15 countries, chosen from a pool of 648 proposals.

Two projects from IGTP funded by ”la Caixa” Foundation to transition their innovative research from the laboratory to patients

The first urine test that detects kidney fibrosis as an alternative to kidney biopsies, an initiative from the IVECAT group, and a project applying artificial intelligence to rapidly categorise stroke patients and enhance their recovery chances, from the Neurovascular Research group, are two of the fifteen projects from Catalan research centres selected within the 2023 call of the new CaixaImpulse Healthcare Innovation programme.